{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T04:31:08Z","timestamp":1777350668539,"version":"3.51.4"},"reference-count":33,"publisher":"Informa UK Limited","issue":"8","funder":[{"name":"Fresenius Kabi Sain S.L.U"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Review of Pharmacoeconomics & Outcomes Research"],"published-print":{"date-parts":[[2023,9,14]]},"DOI":"10.1080\/14737167.2023.2232109","type":"journal-article","created":{"date-parts":[[2023,7,3]],"date-time":"2023-07-03T07:29:27Z","timestamp":1688369367000},"page":"959-965","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":2,"title":["Patient preferences in chronic immune-mediated inflammatory diseases potentially treated with biological drugs: discrete choice analysis using real-world data analysis"],"prefix":"10.1080","volume":"23","author":[{"given":"Daniel","family":"Ginard-Vicens","sequence":"first","affiliation":[{"name":"Gastroenterology Service, Cl\u00ednica Rotger Quironsalud, Palma, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3725-8510","authenticated-orcid":false,"given":"Jes\u00fas","family":"Tornero-Molina","sequence":"additional","affiliation":[{"name":"Rheumatologist, Independent Professional, Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L","family":"Fern\u00e1ndez-Fuente-Burs\u00f3n","sequence":"additional","affiliation":[{"name":"Rheumatologist, Hospital Quironsalud Infanta Luisa, Sevilla, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"ML","family":"Gonz\u00e1lez G\u00f3mez","sequence":"additional","affiliation":[{"name":"Rheumatologist, Hospital Universitario Quironsalud Pozuelo, Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E","family":"Moreno","sequence":"additional","affiliation":[{"name":"Rheumatologist, Hospital Quironsalud Barcelona, Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Salleras","sequence":"additional","affiliation":[{"name":"Dermatologist, Hospital Sagrat Cor, Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"MA","family":"Guigini","sequence":"additional","affiliation":[{"name":"Medical department, Fresenius Kabi Espa\u00f1a, S.A.U, Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6831-3183","authenticated-orcid":false,"given":"A","family":"Burniol-Garcia","sequence":"additional","affiliation":[{"name":"Axentiva Solutions, Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6066-0818","authenticated-orcid":false,"given":"C","family":"Crespo","sequence":"additional","affiliation":[{"name":"Axentiva Solutions, Barcelona, Spain"},{"name":"Department of Statistics, University of Barcelona, Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2023,7,4]]},"reference":[{"issue":"10258","key":"e_1_3_7_2_1","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1016\/S0140-6736(20)30925-9","article-title":"Global burden of 369 Diseases and Injuries in 204 countries and territories, 1990\u20132019: a systematic analysis for the Global Burden of Disease Study 2019","volume":"396","author":"Abbafati C","year":"2020","unstructured":"Abbafati C, Abbas KM, Abbasi-Kangevari M, et al. Global burden of 369 Diseases and Injuries in 204 countries and territories, 1990\u20132019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2020 Oct;396(10258):1204\u20131222.","journal-title":"Lancet"},{"issue":"1","key":"e_1_3_7_3_1","doi-asserted-by":"crossref","first-page":"S17","DOI":"10.1093\/jcag\/gwy055","article-title":"The impact of inflammatory bowel disease in Canada 2018: direct costs and health services utilization","volume":"2","author":"Kuenzig ME","year":"2019","unstructured":"Kuenzig ME, Benchimol EI, Lee L, et al. The impact of inflammatory bowel disease in Canada 2018: direct costs and health services utilization. J Can Assoc Gastroenterol. 2019 Feb;2(Supplement_1):S17\u201333.","journal-title":"J Can Assoc Gastroenterol"},{"issue":"1","key":"e_1_3_7_4_1","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1097\/MIB.0000000000000250","article-title":"Costs and resource utilization for diagnosis and treatment during the initial year in a European inflammatory bowel disease inception cohort: an ECCO-EpiCom study","volume":"21","author":"Burisch J","year":"2015","unstructured":"Burisch J, Vardi H, Pedersen N, et al. Costs and resource utilization for diagnosis and treatment during the initial year in a European inflammatory bowel disease inception cohort: an ECCO-EpiCom study. Inflamm Bowel Dis. 2015 Jan;21(1):121\u2013131.","journal-title":"Inflamm Bowel Dis"},{"issue":"5","key":"e_1_3_7_5_1","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/S2468-1253(20)30012-1","article-title":"Health-care costs of inflammatory bowel disease in a pan-European, community-based, inception cohort during 5 years of follow-up: a population-based study","volume":"5","author":"Burisch J","year":"2020","unstructured":"Burisch J, Vardi H, Schwartz D, et al. Health-care costs of inflammatory bowel disease in a pan-European, community-based, inception cohort during 5 years of follow-up: a population-based study. Lancet Gastroenterol Hepatol. 2020 May;5(5):454\u2013464.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"e_1_3_7_6_1","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjz203.872"},{"issue":"9","key":"e_1_3_7_7_1","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/j.gastrohep.2015.03.001","article-title":"Incidence and phenotype at diagnosis of inflammatory bowel disease. Results in Spain of the EpiCom study","volume":"38","author":"Fern\u00e1ndez A","year":"2015","unstructured":"Fern\u00e1ndez A, Hern\u00e1ndez V, Mart\u00ednez-Ares D, et al. Incidence and phenotype at diagnosis of inflammatory bowel disease. Results in Spain of the EpiCom study. Gastroenterol Hepatol. 2015 Nov;38(9):534\u2013540.","journal-title":"Gastroenterol Hepatol"},{"issue":"1","key":"e_1_3_7_8_1","doi-asserted-by":"crossref","first-page":"e001450","DOI":"10.1136\/rmdopen-2020-001450","article-title":"Prevalence and distribution of peripheral musculoskeletal manifestations in spondyloarthritis including psoriatic arthritis: results of the worldwide, cross-sectional ASAS-PerSpA study","volume":"7","author":"L\u00f3pez-Medina C","year":"2021","unstructured":"L\u00f3pez-Medina C, Molto A, Sieper J, et al. Prevalence and distribution of peripheral musculoskeletal manifestations in spondyloarthritis including psoriatic arthritis: results of the worldwide, cross-sectional ASAS-PerSpA study. RMD Open. 2021 Jan;7(1):e001450.","journal-title":"RMD Open"},{"issue":"9","key":"e_1_3_7_9_1","doi-asserted-by":"crossref","first-page":"2896","DOI":"10.3390\/jcm9092896","article-title":"Time trends of crohn\u2019s disease in Catalonia from 2011 to 2017. increasing use of biologics correlates with a reduced need for surgery","volume":"9","author":"Brunet E","year":"2020","unstructured":"Brunet E, Vela E, Melcarne L, et al. Time trends of crohn\u2019s disease in Catalonia from 2011 to 2017. increasing use of biologics correlates with a reduced need for surgery. J Clin Med. 2020 Sep;9(9):2896.","journal-title":"J Clin Med"},{"key":"e_1_3_7_10_1","doi-asserted-by":"publisher","DOI":"10.7399\/fh.11280"},{"key":"e_1_3_7_11_1","unstructured":"European Medicines Agency. Revised framework for interaction between the European Medicines Agency and patients and consumers and their organisations. EMA\/637573\/2014. 2014."},{"key":"e_1_3_7_12_1","volume-title":"Examining the role of patient preferences to inform regulatory decisions","author":"Reed SD","year":"2018","unstructured":"Reed SD, Reaney M, Shuren J, et al. Examining the role of patient preferences to inform regulatory decisions. Baltimore: MD: ISPOR; 2018."},{"issue":"2","key":"e_1_3_7_13_1","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1111\/j.1369-7625.2004.00267.x","article-title":"Agreement between prostate cancer patients and their clinicians about utilities and attribute importance","volume":"7","author":"Elstein AS","year":"2004","unstructured":"Elstein AS, Chapman GB, Chmiel JS, et al. Agreement between prostate cancer patients and their clinicians about utilities and attribute importance. Health Expect. 2004 Jun; 7(2):115\u2013125. InternetAvailable from http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/15117386","journal-title":"Health Expect"},{"issue":"3","key":"e_1_3_7_14_1","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1177\/0272989X9801800304","article-title":"Prostate cancer patients\u2019 utilities for health states: how it looks depends on where you stand","volume":"18","author":"Chapman GB","year":"1998","unstructured":"Chapman GB, Elstein AS, Kuzel TM, et al. Prostate cancer patients\u2019 utilities for health states: how it looks depends on where you stand. Med Decis Making. 1998;18(3):278\u2013286. InternetAvailable from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/9679992","journal-title":"Med Decis Making"},{"key":"e_1_3_7_15_1","unstructured":"European Medicines Agency. Reflection paper on the regulatory guidance for the use of health-related quality of life (HRQoL) measures in the evaluation of medicinal products. EMEA\/CHMP\/EWP\/139391\/2004. London; 2005."},{"key":"e_1_3_7_16_1","volume-title":"Food and Drugs Administration C for DE and R (CDER). Guidance for industry and FDA Staff. Qualification process for drug development tools","author":"U.S. Department of Health and Human Services","year":"2014","unstructured":"U.S. Department of Health and Human Services. Food and Drugs Administration C for DE and R (CDER). Guidance for industry and FDA Staff. Qualification process for drug development tools. Silver Spring: MD: U.S. Department of Health and Human Services; 2014."},{"key":"e_1_3_7_17_1","unstructured":"European Medicines Agency. Patients\u2019 and Consumers\u2019 Working Party."},{"issue":"2","key":"e_1_3_7_18_1","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1177\/2168479017716715","article-title":"Assessing the financial value of patient engagement: a quantitative approach from CTTI\u2019s patient groups and clinical trials project","volume":"52","author":"Levitan B","year":"2018","unstructured":"Levitan B, Getz K, Eisenstein EL, et al. Assessing the financial value of patient engagement: a quantitative approach from CTTI\u2019s patient groups and clinical trials project. Ther Innov Regul Sci. 2018 Mar;52(2):220\u2013229.","journal-title":"Ther Innov Regul Sci"},{"issue":"1","key":"e_1_3_7_19_1","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1186\/s12961-017-0263-z","article-title":"Collaborative action for person-centred coordinated care (P3C): an approach to support the development of a comprehensive system-wide solution to fragmented care","volume":"15","author":"Lloyd HM","year":"2017","unstructured":"Lloyd HM, Pearson M, Sheaff R, et al. Collaborative action for person-centred coordinated care (P3C): an approach to support the development of a comprehensive system-wide solution to fragmented care. Health Res Policy Syst. 2017 Nov;15(1):98.","journal-title":"Health Res Policy Syst"},{"issue":"1","key":"e_1_3_7_20_1","doi-asserted-by":"crossref","first-page":"s-7-s","DOI":"10.1089\/acm.2005.11.s-7","article-title":"Finding common ground: patient-centeredness and evidence-based chronic illness care","volume":"11","author":"Wagner EH","year":"2005","unstructured":"Wagner EH, Bennett SM, Austin BT, et al. Finding common ground: patient-centeredness and evidence-based chronic illness care. J Altern Complement Med. 2005 Dec;11(supplement 1):s-7-s\u201315.","journal-title":"J Altern Complement Med"},{"key":"e_1_3_7_21_1","doi-asserted-by":"publisher","DOI":"10.1377\/hlthaff.20.6.64"},{"key":"e_1_3_7_22_1","first-page":"1037","volume-title":"Med Care","author":"Wagner EH.","year":"2004","unstructured":"Wagner EH. Effective teamwork and quality of care. Med Care. 2004;42(11):1037\u20131039."},{"issue":"5","key":"e_1_3_7_23_1","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1007\/s40271-019-00367-w","article-title":"Patient preferences in the medical product life cycle: what do stakeholders think? Semi-structured qualitative interviews in Europe and the USA","volume":"12","author":"Janssens R","year":"2019","unstructured":"Janssens R, Russo S, van Overbeeke E, et al. Patient preferences in the medical product life cycle: what do stakeholders think? Semi-structured qualitative interviews in Europe and the USA. Patient. 2019 Oct;12(5):513\u2013526.","journal-title":"Patient"},{"key":"e_1_3_7_24_1","doi-asserted-by":"publisher","DOI":"10.5301\/jn.5000132"},{"key":"e_1_3_7_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/0038-0121(76)90036-7"},{"key":"e_1_3_7_26_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40271-015-0118-z"},{"issue":"3","key":"e_1_3_7_27_1","doi-asserted-by":"crossref","first-page":"13","DOI":"10.5334\/ijic.2443","article-title":"Development and validation of an instrument for assessing patient experience of chronic illness care","volume":"16","author":"Mira JJ","year":"2016","unstructured":"Mira JJ, Nu\u00f1o-Solin\u00eds R, Guilabert-Mora M, et al. Development and validation of an instrument for assessing patient experience of chronic illness care. Int J Integr Care. 2016 Aug;16(3):13.","journal-title":"Int J Integr Care"},{"key":"e_1_3_7_28_1","unstructured":"NHS. Outpatients Questionnaire. 2011; Available from: https:\/\/sp.ukdataservice.ac.uk\/doc\/5091\/mrdoc\/pdf\/5091userguide2003.pdf"},{"key":"e_1_3_7_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2010.11.013"},{"issue":"1","key":"e_1_3_7_30_1","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.jval.2012.08.2223","article-title":"Constructing experimental designs for discrete-choice experiments: report of the ISPOR conjoint analysis experimental design good research practices task force","volume":"16","author":"Johnson FR","year":"2013","unstructured":"Johnson FR, Lancsar E, Marshall D, et al. Constructing experimental designs for discrete-choice experiments: report of the ISPOR conjoint analysis experimental design good research practices task force. Value Heal. 2013 Jan;16(1):3\u201313.","journal-title":"Value Heal"},{"key":"e_1_3_7_31_1","doi-asserted-by":"crossref","DOI":"10.1017\/S1930297500004952","article-title":"Predicting biases in very highly educated samples: numeracy and metacognition","volume":"9","author":"Ghazal S","year":"2014","unstructured":"Ghazal S, Cokely ET, Garcia-Retamero R. Predicting biases in very highly educated samples: numeracy and metacognition. Judgm Decis Mak. 2014. 9.","journal-title":"Judgm Decis Mak"},{"key":"e_1_3_7_32_1","doi-asserted-by":"publisher","DOI":"10.1002\/hec.729"},{"issue":"9","key":"e_1_3_7_33_1","doi-asserted-by":"crossref","first-page":"e386","DOI":"10.1016\/j.crohns.2013.03.001","article-title":"An exploration of the follow-up up needs of patients with inflammatory bowel disease","volume":"7","author":"Kemp K","year":"2013","unstructured":"Kemp K, Griffiths J, Campbell S, et al. An exploration of the follow-up up needs of patients with inflammatory bowel disease. J Crohns Colitis. 2013 Oct;7(9):e386\u201395.","journal-title":"J Crohns Colitis"},{"issue":"10","key":"e_1_3_7_34_1","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1016\/j.dld.2016.06.036","article-title":"Patient satisfaction in the management of mild-to-moderate ulcerative colitis: results of a Delphi study among patients and physicians","volume":"48","author":"Casellas F","year":"2016","unstructured":"Casellas F, Ginard D, Riestra S. Patient satisfaction in the management of mild-to-moderate ulcerative colitis: results of a Delphi study among patients and physicians. Dig Liver Dis. 2016 Oct;48(10):1172\u20131179. InternetAvailable from. https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1590865816305126","journal-title":"Dig Liver Dis"}],"container-title":["Expert Review of Pharmacoeconomics & Outcomes Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14737167.2023.2232109","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,25]],"date-time":"2023-09-25T10:30:57Z","timestamp":1695637857000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14737167.2023.2232109"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,4]]},"references-count":33,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2023,9,14]]}},"alternative-id":["10.1080\/14737167.2023.2232109"],"URL":"https:\/\/doi.org\/10.1080\/14737167.2023.2232109","relation":{},"ISSN":["1473-7167","1744-8379"],"issn-type":[{"value":"1473-7167","type":"print"},{"value":"1744-8379","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,4]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ierp20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ierp20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2023-02-23","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-06-08","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-07-04","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}